The rapid response to developing vaccines to the disease and the use of novel methods, such as messenger RNA, to do so has created optimism the same speed and execution is possible for a host of other viruses and more broadly to effectively create the longevity escape velocity – where people’s life expectancy increases by more than a year for each year they live.
But research and startups is just part of the challenge in a geopolitical world with concern about sovereignty of supply and requirements for manufacturing bases as well as requirements to carry our large-scale trials.
The UK plans to build on the recovery trial, which uncovered two treatments for covid-19, by streamlining research and embedding it in the health service and through fast regulation.
UK-based venture capital firm Abingworth this month raised $582m for its second clinical co-development fund.
Abingworth has previously invested through its co-development portfolio companies, Avillion and SFJ Pharmaceuticals, which both finance and facilitate clinical trials, taking on all of the clinical and regulatory risk in return for a pre-agreed return if the drug is approved.
When Abingworth first got into clinical co-development back in 2009, it primarily worked with pharma companies who only paid out if the project was successful, by which time the cost of the deal could be amortized over the sales of the product.
The market has since expanded to cover biotechs, which want to reduce the dilutive impact if they had to go out and raise the money on the public market. And there are plenty more of them.
The Financial Times noted Magdalen College was selling a 40% stake in the Oxford Science Park “after a surge of investor interest in the fast-growing life sciences sector increased the site’s value almost seven-fold in five years”.
As sole owner of the park since 2016, Magdalen has invested in new labs and research space on the site and gained planning consent for a new 165,000 square foot development to support its more than 100 businesses based there, including Vaccitech, which raised $111m from an initial public offering on the Nasdaq stock exchange in April.
Last year British firms raised £1.4bn ($2bn) of venture capital, the Economist said, which was more than anywhere else in Europe but less than the American hubs, Massachusetts (£4.7bn) and San Francisco (£4.5bn).
But the parallels between the UK and US are growing.
A few years ago, Seth Harrison, an American venture capitalist at Apple Tree Partners, was looking to open an office in Europe. The choice came down to Britain or Switzerland, he told the Economist. “I got quite acquainted with the whole UK biotech scene.
“The fantastic research ferment that occurs in the Golden Triangle. You know, the London, Cambridge, Oxford area…And I just said: ‘Wow, this reminds me of Cambridge, Massachusetts, 25 years ago.’”
To learn more about the golden triangle, our sister publication will start its review of the three university-led ecosystems, starting with Imperial College, London, in July before discussion and interaction at the GCV Symposium in November.
